Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease

Authors:
  • NWNoel S. Weiss
    Noel S. Weiss
  • CFCurt D. Furberg
    Curt D. Furberg
  • TKThomas D. Koepsell
    Thomas D. Koepsell
  • DSDavid S. Siscovick
    David S. Siscovick
  • FRFrits R. Rosendaal
    Frits R. Rosendaal
  • NSNicholas L. Smith
    Nicholas L. Smith
  • SHSusan R. Heckbert
    Susan R. Heckbert
  • RKRobert C. Kaplan
    Robert C. Kaplan
  • DLDanyu Lin
    Danyu Lin
  • TFThomas R. Fleming
    Thomas R. Fleming
  • EWEdward H. Wagner
    Edward H. Wagner

Abstract
Data on surrogate end points such as blood pressure or body weight have often been used to support the approval of new pharmacologic treatments for cardiovasc

This publication has 20 references indexed in Scilit: